Modality
Fusion Protein
MOA
EGFRi
Target
JAK2
Pathway
Proteasome
RA
Development Pipeline
Preclinical
Feb 2023
PreclinicalCurrent
NCT06718490
868 pts·RA
2023-02→TBD·Completed
868 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Trial Timeline
Preclinical
Complet…
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06718490 | Preclinical | RA | Completed | 868 | ORR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Niranesiran | Johnson & Johnson | Phase 2 | KIF18A | |
| JNJ-5094 | Johnson & Johnson | Phase 2/3 | GIP-R | |
| GSK-2051 | GSK | Phase 1 | PSMA | |
| GIL-8529 | Gilead Sciences | Phase 1/2 | JAK1 | |
| GMA-5010 | Genmab | Phase 3 | JAK2 | |
| 207-2754 | Samsung Biologics | Phase 1/2 | KRASG12D | |
| Teravorutinib | Illumina | Phase 2 | JAK2 | |
| Mavuratamab | Blueprint Medicines | NDA/BLA | BET | |
| Bemaderotide | Revolution Medicines | Phase 3 | BCL-2 | |
| AXS-4984 | Axsome | Preclinical | JAK2 |